英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

aristo pharma ltd - esomeprazole magnesium dihydrate - gastro-resistant capsule - 20mg

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.37 mg - capsule, enteric - excipient ingredients: triethyl citrate; dimeticone 350; diacetylated monoglycerides; sucrose; gelatin; maize starch; mannitol; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; purified talc; stearoyl macrogolglycerides; polysorbate 80; hypromellose; purified water - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: titanium dioxide; purified water; dimeticone 350; mannitol; gelatin; stearoyl macrogolglycerides; maize starch; iron oxide yellow; diacetylated monoglycerides; triethyl citrate; sucrose; hypromellose; purified talc; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1) - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer